InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report released on Tuesday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital began coverage on InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 target price on the stock.

InspireMD Stock Performance

NSPR opened at $2.80 on Tuesday. The stock’s 50-day moving average price is $2.85 and its 200 day moving average price is $2.76. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.80. The firm has a market cap of $83.13 million, a price-to-earnings ratio of -3.73 and a beta of 0.88.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Parkman Healthcare Partners LLC lifted its position in InspireMD by 721.2% during the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock worth $2,248,000 after acquiring an additional 750,635 shares during the period. Essex Investment Management Co. LLC acquired a new stake in InspireMD during the 4th quarter worth approximately $191,000. Northern Trust Corp lifted its position in InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after acquiring an additional 24,452 shares during the period. Schonfeld Strategic Advisors LLC lifted its position in InspireMD by 153.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after acquiring an additional 18,233 shares during the period. Finally, Legato Capital Management LLC acquired a new stake in InspireMD during the 4th quarter worth approximately $47,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.